Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00264550 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 3 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 3
- Development phase
- 444
- Enrollment target
NCT00264550 is a Phase 3 study that has completed, run by Centocor. The registered enrollment target is 444 participants.
The verdict
NCT00264550, a Phase 3 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 444 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate (MTX), as compared to methotrexate alone in rheumatoid arthritis (RA) patients who have active rheumatoid arthritis despite treatment with MTX.
Interventions
- DRUG Placebo capsules
- DRUG Methotrexate
- DRUG Placebo injection
- DRUG Golimumab 100 mg
- DRUG Golimumab 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2005-12 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00264550
The ClinicalTrials.gov registry entry for NCT00264550 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo capsules is the first listed.
NCT00264550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00264550 about?
NCT00264550 is a clinical study titled "An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy". The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate (MTX), as compared to methotrexate alone in rheumatoid arthritis (RA) patients who have active rheumatoid arthritis despite treatment with MTX.
What is the current status of trial NCT00264550?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 444 participants. The study started on 2005-12. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00264550?
The interventions under investigation include: Placebo capsules (DRUG), Methotrexate (DRUG), Placebo injection (DRUG), Golimumab 100 mg (DRUG), Golimumab 50 mg (DRUG).
Who is sponsoring clinical trial NCT00264550?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.